Evolution in the management of non-small cell lung cancer in Brazil

Fernandes, Constantino José

doi:10.1590/s1806-37562017000060002

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pathway enrichment, we found that the pathways directly associated with LC were non-small-cell lung cancer (hsa05223) and small cell lung cancer (hsa05222). Histological subtypes of LC mainly included NSCLC and SCLC; approximately 85% of all LC cases are NSCLC, and 15% are SCLC [97, 98]. In addition, pathways in cancer (hsa05200) were identified as a significant pathway in LC treatment with the highest number of genes.…”

Section: Discussionmentioning

confidence: 99%

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Meng

Liu

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Compound Kushen Injection (CKI) is a Chinese patent drug that shows good efficacy in treating lung cancer (LC). However, its underlying mechanisms need to be further clarified. Methods. In this study, we adopted a network pharmacology method to gather compounds, predict targets, construct networks, and analyze biological functions and pathways. Moreover, molecular docking simulation was employed to assess the binding potential of selected target-compound pairs. Results. Four networks were established, including the compound-putative target network, protein-protein interaction (PPI) network of LC targets, compound-LC target network, and herb-compound-target-pathway network. Network analysis showed that 8 targets (CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9) may be the therapeutic targets of CKI in LC. In addition, molecular docking simulation indicated that CHRNA3, DRD2, PRKCA, CDK1, CDK2, MMP1, and MMP9 had good binding activity with the corresponding compounds. Furthermore, enrichment analysis indicated that CKI might exert a therapeutic role in LC by regulating some important pathways, namely, pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, non-small-cell lung cancer, and small cell lung cancer. Conclusions. This study validated and predicted the mechanism of CKI in treating LC. Additionally, this study provides a good foundation for further experimental studies and promotes the reasonable application of CKI in the clinical treatment of LC.

show abstract

Section: Discussionmentioning

confidence: 99%

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Meng

Liu

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Different cancer types carry different VTE risk. Haematological malignancies, lung, pancreas, stomach, bowel and brain cancers are associated with a high risk of clot formation [16,17], whilst prostate and breast cancers are associated with low risk of thrombosis [18]. Nevertheless, despite the low relative risk, since prostate and breast are two of the most prevalent cancers worldwide, VTE is commonly seen in these populations.…”

Section: Cat Risk Factorsmentioning

confidence: 99%

Cancer-associated thrombosis: the when, how and why

et al. 2019

View full text Add to dashboard Cite

Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.

show abstract

“…Cancer-associated thrombosis (CAT) is a significant issue, both for medical specialists that deal with VTE and for oncologists. 48,49 It is believed that approximately 20% of VTE patients have or will have cancer over a short period of time and that 20% of all cancer patients will present VTE during their clinical course. 50 Furthermore, cancer is a significant cause of death in VTE patients and vice versa .…”

Section: Should Long-term Anticoagulation Be Provided For Cancer-assomentioning

confidence: 99%

Extended anticoagulation after venous thromboembolism: should it be done?

Fernandes

Calderaro

Piloto

et al. 2019

Ther Adv Respir Dis

View full text Add to dashboard Cite

Most physicians understand venous thromboembolism (VTE) to be an acute and time-limited disease. However, pathophysiological and epidemiological data suggest that in most patients VTE recurrence risk is not resolved after the first 6 months of anticoagulation. Recurrence rates are high and potentially life-threatening. In these cases, it would make sense to prolong anticoagulation for an undetermined length of time. However, what about the bleeding rates, induced by prolonged anticoagulation? Would they not outweigh the benefit of reducing the VTE recurrent risk? How long should anticoagulation be continued, and should all patients suffering from VTE be provided with extended anticoagulation? This review will address the most recent data concerning extended anticoagulation in VTE secondary prophylaxis. The reviews of this paper are available via the supplementary material section.

show abstract

Evolution in the management of non-small cell lung cancer in Brazil

Cited by 6 publications

References 19 publications

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Cancer-associated thrombosis: the when, how and why

Extended anticoagulation after venous thromboembolism: should it be done?

Contact Info

Product

Resources

About